Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3189 - Expression of Steroid Hormone Transporter, SLCO1B3, is Mediated by a CBP/p300 Regulatory Mechanism in Prostate Cancer


10 Sep 2017


Poster display session


Translational Research;  Prostate Cancer


Edel McCrea


Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370


E.M. McCrea1, P.A. Huang2, E.M. Harris2, J.D. Strope2, T.M. Sissung2, D.K. Price1, C.H. Chau1, W.D. Figg2

Author affiliations

  • 1 Genitorurinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, 20892 - Bethesda/US
  • 2 Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, 20892 - Bethesda/US


Abstract 3189


Recent studies support the role of steroid hormone transporters in modulating intratumoral androgen concentrations, thereby promoting castration-resistant prostate cancer (CRPC) progression. The organic anion polypeptide 1B3 (OATP1B3) transporter is expressed de novo in prostate tumors and contributes to the transport of androgen into these cells. Polymorphic variations in the SLCO1B3 gene encoding OATP1B3 are related to clinical outcome in men with prostate cancer receiving androgen deprivation therapy (ADT) or those with CRPC. The current study elucidates the mechanism of de novo SLCO1B3 expression in prostate cancer. We discovered that chetomin, a known inhibitor of HIF-1α- and CBP/p300 binding, was a potent inducer of SLCO1B3 transcripts.


We investigated the transcriptional regulation of SLCO1B3 expression by CBP/p300 using siRNA-mediated gene silencing or treatment with various CBP/p300 inhibitors (C646, HATi II) to determine the effects on gene transcription, downstream pathways, and transporter-dependent uptake studies.


Treatment with various CBP/p300 inhibitors (CH1 or HAT binding domains) significantly increased the expression of SLCO1B3 and subsequent transporter-mediated androgen uptake in tumor cells. Specific downregulation of p300 or CBP by siRNA reduced SLCO1B3 expression in prostate cancer cells (22Rv1, LNCaP, and PC3), suggesting that CBP/p300 interacts with specific transcription factors essential for driving SLCO1B3 expression. Cells treated with ADT elicited differential effects on transporter expression in AR-positive vs AR-null cells. Studies are currently underway to identify cofactors involved in forming the CBP/p300 transcriptional complex regulating SLCO1B3 expression.


De novo OATP1B3 expression in prostate cancer is a mechanism of tumoral resistance to ADT resulting in greater androgen uptake. Taken together, the data suggest that ADT resistance and transporter-dependent increased uptake of residual androgens result from CBP/p300-mediated SLCO1B3 expression. OATP1B3 should be considered a viable biological target for therapeutic intervention in prostate cancer.

Clinical trial identification

Legal entity responsible for the study

National Institutes of Health


National Cancer Institute (NIH)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.